This project aims to assess effectiveness of the cervical cancer vaccine introduced in 2005 by comparing current HPV types circulating in the population to the pre-vaccine data.
This study can potentially identify differences in prevalence of HPV types in the population after introduction of the vaccine including early predictions of any replacement genotypes.
Such early indications on how the vaccine is working can assist in determining if modifications to types are needed.
A/Prof Sepehr Tabrizi, Dr Julia Brotherton, Dr Matthew Stevens
Department of Microbiology, Royal Women's Hospital